Psychometric Evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)—A Measure of Symptom Distress  by Arbuckle, Robert A. et al.
Psychometric Evaluation of the Diabetes Symptom
Checklist-Revised (DSC-R)—A Measure of Symptom Distressvhe_571 1168..1175
Robert A. Arbuckle, MA,1 Louise Humphrey, MSc,1 Kawitha Vardeva, MSc,2 Bhakti Arondekar, PhD, MBA,3
Muriel Danten-Viala, MSc,4 Jane A. Scott, PhD,1 Frank J. Snoek, PhD5
1Mapi Values, Bollington, UK; 2Amgen Ltd, Cambridge, UK; 3GlaxoSmithKline, Philadelphia, PA, USA; 4Mapi Values, Lyon, France; 5VU University
Medical Center,Amsterdam,The Netherlands
ABSTRACT
Objective: To assess the psychometric validity, reliability, responsiveness,
and minimal important differences of the Diabetes Symptoms Checklist-
Revised (DSC-R), a widely used patient-reported outcome measure of
diabetes symptom distress.
Research Design and Methods: Psychometric validity of the DSC-R was
assessed using blinded data from a large-scale trial of approximately 4000
type 2 diabetes patients. Conﬁrmatory factorial analysis (CFA) and mul-
titrait analysis were used to examine the construct validity of the structure
of DSC-R. DSC-R internal consistency, discriminative validity, and respon-
siveness were also assessed. Distribution and anchor-based methods were
used to estimate minimal important differences for DSC-R domains.
Results: Mean age of the sample was 56 years, 42% were female, 88%
were Caucasian. Patients had a mean body mass index (BMI) of 32.2 and
mean glucose-fasting level of 151.7 md/dl. CFA and multitrait analysis
indicated that the scoring of the DSC-R has acceptable construct validity.
Item-scale correlations ranged from 0.44 to 0.78. Cronbach’s alpha coef-
ﬁcients ranged from 0.69 to 0.87. At baseline, DSC-R scores were higher
among patients with higher BMI scores (P < 0.0001), supporting the dis-
criminative validity of the DSC-R. Minimal important difference estimates
ranged from 0.39 to 0.60 points when using distribution methods and
from 0.00 to 0.33 when estimated using anchor-based methods.
Conclusions: The DSC-R demonstrated excellent psychometric properties
when tested in a large-scale diabetes clinical trial. Responsiveness and
test–retest reliability of the DSC-R warrant further evaluation.
Keywords: diabetes, patient reported outcome, psychometric validation,
quality of life, symptom distress.
Introduction
There is general consensus that quality of life is an important
outcome of diabetes care, requiring reliable patient-reported
measures, pertaining to the physical, social, and psychological
domains [1]. The Diabetes Symptoms Checklist (DSC) was devel-
oped to capture the subjective experience of diabetes-related
symptoms and changes therein as a result of medical treatment
[2]. Symptoms associated with type 2 diabetes may be directly
related to hyperglycemia (e.g., excessive thirst, dryness of the
mouth, fatigue, frequent urination), complications associated
with diabetes (e.g., loss of sensation in the extremities), and the
treatment of diabetes (e.g., hypoglycemia) [3].
The DSC items were derived from a review of the literature
and discussions with experienced physicians in the ﬁeld [2].
Guided by their clinical knowledge, the developers identiﬁed
eight domains of importance for diabetes symptom distress. A
ﬁnal selection of 34 items measuring these eight domains was
made based on psychometric criteria. Based on research ﬁndings
[4–6], the developers of the instrument later sought to improve
the DSC in two ways. First, the frequency scale was replaced by
a dichotomous “yes” or “no” response for the presence or
absence of each symptom. This change was made because at
times patients found the dual response format confusing to
answer and missing data could be a problem. Moreover, reported
frequency and burden were generally highly intercorrelated
(>0.80), suggesting redundancy. The second change was to
change the scaling from a 4-point to a 5-point Likert scale. No
changes to item content were made. The resulting instrument is
known as the DSC-Revised (DSC-R).
Validity and reliability for the DSC-R have not been reported
in the literature, although recent studies would suggest DSC-R
has satisfactory reliability in both newly diagnosed and insulin-
treated type 2 diabetes patients [7–11]. To address the need for
evidence of psychometric validity, blinded, post hoc analysis of
data from a large scale, multicenter, randomized controlled clini-
cal trial was performed to assess the psychometric properties of
DSC-R.
Subjects and Methods
Post hoc psychometric validation analyses were performed using
blinded data from A Diabetes Outcome Progression Trial
(ADOPT) [12]. The ADOPT study was a double-blind, random-
ized, parallel group study comparing rosiglitazone, metformin,
and glyburide as an initial treatment for 4360 recently diagnosed
patients with type 2 diabetes. Details of the study design are
reported elsewhere [12]. The sample included patients from the
United States (n = 1644), Canada (n = 612), France (n = 388),
Germany (n = 466), Spain (n = 397), UK (n = 313), and other
countries (n = 466). The primary outcome was the time to mono-
therapy failure deﬁned as fasting plasma glucose of more than
180 mg/dl on consecutive testing after at least 6 weeks of treat-
ment at the maximum tolerated dose of study medication. Cross-
sectional psychometric validation analyses (all analyses except
responsiveness and minimal important differences [MID]) were
performed on 4286 patients who completed the DSC-R at
baseline. The 3594 patients who completed the DSC-R and the
Short-Form 36 (SF-36) at 1-year follow-up were included in the
longitudinal analyses.
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Questionnaires
Diabetes Symptom Checklist-Revised
The 34 items of the DSC-R are grouped into eight symptom
clusters or domains, each measuring a different aspect of diabetes
symptomatology: hyperglycemic, hypoglycemic, psychological-
cognitive, psychological-fatigue, cardiovascular, neurological-
pain, neurological-sensory, and ophthalmologic. A conceptual
framework detailing the items included in each domain is pre-
sented in Figure 1. For each item, participants are asked if they
have experienced the symptom in the past 4 weeks, and if yes,
how troublesome that particular symptom is for them. Two
example items demonstrating the format of the questionnaire are
provided in Figure 2. Items are summed to form domain scores
and all items of the DSC-R can be summed together to form a
total score. Higher scores indicate greater symptom burden.
Short-Form 36
The SF-36 is a 36-item measure of perceived health status with
established validity in both healthy subjects and somatic patients
[13–16]. A total score can be calculated as well as a Physical
Component and Mental Component summary score. Domain
scores range from 0 to 100; higher scores indicate better health
status. The recall period is the past 4 weeks.
Clinical Measures
Body mass index (BMI) and HbA1c levels were recorded at both
study visits reported here.
Analysis
All analyses were performed post hoc on blinded data from the
ADOPT clinical trial. With the exception of the analyses of
responsiveness andMID, all analyses were performed on baseline
cross-sectional data. Responsiveness and MID analyses were
assessed using baseline and 1 year (visit 9) data.
Conﬁrmatory factorial analysis (CFA) was used to evaluate
the overall structure of the DSC-R, as shown in Figure 1. The
goodness of ﬁt of the model was assessed based on the Good-
ness of Fit Index (GFI) (good ﬁt if >0.90), the Root Mean
Square Residual (RMR) (good ﬁt if <0.05), the Comparative
Fit Index (CFI) (good if >0.95), and the Root Mean Square
Error of Approximation (RMSEA) ﬁt indices (good ﬁt if <0.05)
[17].
Multitrait analysis was performed to examine the validity of
the DSC-R item-scale structure. This included tests of item con-
vergent validity (the correlation between each item and its own
scale should be 0.40), [18] and internal consistency reliability
(alpha coefﬁcients 0.70 for acceptable internal consistency)
[19]. Percentages scoring at ﬂoor and ceiling (lowest and highest
possible scores) were also examined to check for the presence of
ﬂoor or ceiling effects, and the DSC-R interscale correlations
were examined.
Concurrent validity (also known as convergent/divergent
validity) involves analyzing correlation levels between the scales
of the studied questionnaire and scales of well-established and
validated questionnaires measuring similar concepts [18]. Scales
measuring similar concepts are expected to correlate more highly
than scales measuring unrelated concepts. Concurrent validity
was assessed by examining Spearman’s correlations between the
DSC-R scores and the SF-36 scores.
The known groups validity of the DSC-R (ability to distin-
guish among groups of patients that would be expected to differ
[18]) was evaluated by examining differences in DSC-R scores
according to HbA1c levels (<6%; 6–6.9%; 7–7.9%, 8%) and
BMI levels (<25, 25–29.9, 30–39.9, 40). It was hypothesized
that there would be statistically signiﬁcant differences among the
groups compared (P < 0.05), as assessed using analysis of vari-
ance (ANOVA).
Responsiveness was evaluated by comparing changes in
DSC-R scores from baseline to 1 year later among subgroups of
patients deﬁned by the change score on SF-36 item 2 “compared
to one year ago, how would you rate your health in general
now?” Only patients who completed the DSC-R at both visits
were included in this analysis. Effect sizes were calculated. The
effect size is calculated as the mean difference (change score) in
scores from baseline to 1 year later divided by the standard
deviation of the baseline score. Effect sizes of 0.2, 0.5, and 0.8
were considered small, moderate, and large, respectively, as
deﬁned by Cohen [20]. Effect sizes were expected to be moderate
or large (>0.50) in the expected direction for patients who
Figure 1 Example items showing the format of the Diabetes Symptoms Checklist-Revised.
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reported their health to have improved or worsened, and small or
negligible (<0.25) for patients who reported having experienced
no change in their health.
An MID for a patient reported outcome (PRO) has been
deﬁned as the “smallest difference in score in the domain of
interest which patients perceive as beneﬁcial, and which would
mandate, in the absence of troublesome side effects and excessive
cost, a change in patient’s management” [21]. It is recommended
that more than one method of estimating MID is employed—
thus in the present study both distribution-based and anchor-
based methods were used. First, an effect size of 0.5 (a change of
0.5 of a standard deviation) was considered to be clinically
signiﬁcant (distribution method) [22]. Second, the MID was con-
sidered to be the change in DSC-R scores for patients who
considered their health to be “somewhat better” or “somewhat
worse” in response to the SF-36 item 2 “compared to one year
ago, how would you rate your health in general now?” (anchor-
based method).
For all analyses, the threshold for signiﬁcance was P < 0.05.
Where correlations were evaluated, Pearson’s correlation coefﬁ-
cient was used. ANOVA was used in the comparison of groups.
All data processing and analyses were performed using SAS
software (Statistical Analysis System, Version 9, SAS Institute,
Cary, NC).
Results
Cross-sectional analyses were performed on 4286 randomized
patients. Mean age for the overall population was 56 years.
Forty-two percent of the sample was female; 88% were Cauca-
sian, 2% were Asian, 4% were black, 5% were Hispanic, and
1% other. Mean BMI was 32.2; mean waist–hip ratio was 0.95;
mean number of years with diabetes was 0.8 years; mean HbA1c
was 7.36, and the mean glucose-fasting level was 151.7 md/dl.
The number of missing data was very low for all items, with
less than 3% of missing data for all items, at all study visits. At
Psychological fatigue
1 – Lack of strength (energy)?
4 – An overall sense of fatigue?
17 – Increasing fatigue during the course of the day?
20 – Fatigue in the morning when getting up?
8 – Moodiness?
19 – Irritability just before a meal?
27 – Easily irritated or annoyed?
6 – Sleepiness or drowsiness?
7 – Difficulty concentrating?
31 – Dull head?
33 – Difficulty staying attentive?
2 – Aching calves when walking?
15 – Burning pain in the calves at night?
21 – Shooting pains in the legs?
25 – Burning pain in the legs during day?
29 – Odd feeling in legs or feet when touching?
34 – Tingling or prickling sensations in legs or feet?
3 – Numbness (loss of sensation) in feet?
9 – Numbness (loss of sensation) in the hands?
11 – Tingling sensations in the limbs at night?
26 – Tingling or prickling sensation in hands or fingers?
5 – Shortness or breath at night?
13 – Palpitations or pains in the breast or heart region?
24 – Pains in the breast or heart region?
30 – Shortness of breath during exercise?
10 – Persistently blurred vision (also with glasses on )?
14 – Deteriorating vision?
18 – Flashes or black spots in the field of vision?
22 – Fluctuating clear and blurred vision?
28 – Sudden deterioration of vision?
12 – Very thirsty?
16 – Dry mouth?
23 – Frequent voiding?
32 – Drinking a lot (all sort of beverage)?
Neuropathic pain
Neuropathic sensoric
Cardiovascular
Psychological 
cognitive
Ophtalmologic
Hypoglycemic
Hyperglycemic
0.33
0.60
0.81
0.84
0.68
0.66
0.81
0.69
0.69
0.77
DSC-R Total 
Score
Figure 2 Original model of the Diabetes Symptoms Checklist-Revised tested by conﬁrmatory factorial analysis. Figures on single arrows: factor loadings; ﬁgures on
two-headed curved arrows, correlations among factors; item errors are not shown.
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baseline, the percentage of missing data for the DSC-R
items ranged from 0.37% (n = 16) missing for item 15 “Pain in
calves at night” to 1.63% missing for item 23 “Frequent
voiding.” Thus, there was considered to be an excellent quality of
completion.
The model ﬁt indices for the CFA all narrowly failed to meet
the criteria for acceptability: the GFI was 0.9022, the RMR was
0.0522, the CFI was 0.9029, and the RMSEA was 0.055 (90%
lower conﬁdence limit: 0.0538). Standardized factor loadings
ranged from 0.50 to 0.85—all were well above the 0.40 thresh-
old used as a rule of thumb for acceptable factor loadings.
Scaling test results are summarized in Table 1. Item-domain cor-
relations ranged from 0.44–0.78; thus all items met the test of
item convergent validity (a correlation of >0.40 between the item
and the other items in its domain).
Almost all of the scales surpassed the 0.70 threshold for
acceptable internal consistency reliability (Cronbach’s alpha
range: 0.69–0.87). “Cardiovascular” was the single exception,
with an alpha coefﬁcient of 0.69, just below the alpha threshold.
Across all of the domains there was a high ﬂoor effect (for each
domain the percentages of patients with lowest possible score
ranged from 27.8% to 60.2%), reﬂecting the fact that many
patients gave the response “Did not occur” for all the items in
those domains. Zero-order interdomain correlations ranged from
r = 0.39 (between Neuropathic Sensory and Hyperglycemic
domains) to r = 0.71 (between Psychological Fatigue and Psycho-
logical Cognitive domains). Neuropathic Sensory and Neuro-
pathic Pain domains showed a zero-order correlation of 0.62.
Thus, we believe that the domains are related but not redundant.
Correlations between the DSC-R scale scores and the SF-36
scale scores ranged from -0.22 to -0.69 and were mostly small to
moderate (Table 2). Scales measuring concepts that would be
expected to be related correlated the most highly. For example,
the highest correlation was between the DSC-R Psychological
Fatigue domain and the SF-36 Vitality scale (r = -0.69), both of
which measure fatigue/vitality. Similarly, the DSC-R Neuropathic
Pain domain correlated most highly with the SF-36 Bodily Pain
scale (r = -0.38) and the DSC-R Hypoglycemic domain (which
includes items asking about mood and irritability) correlated
most highly with the SF-36 Mental Health scale (r = -0.45) and
the Mental Component Scale (r = -0.45).
Known groups validity results are summarized in Table 3.
There were statistically signiﬁcant differences in all DSC-R scale
scores among the four groups determined by HbA1c level
(P < 0.005). For all DSC-R scales among the three groups <6%,
6% to 6.9% and 7% to 7.9%, there was a clear linear progres-
sion of higher DSC-R scores for higher HbA1c levels. However,
with the exceptions of the Neuropathic pain and Ophthal-
mologic scales, the 8% group did not continue this
progression—for all other DSC-R scales scores for this group
were slightly lower than for the 7% to 7.9% group. For all
DSC-R scales, there was a linear pattern of higher DSC-R scores
(indicating greater symptom bother) for patients with higher
BMI, with statistically signiﬁcant differences among the groups
(P < 0.0001).
Responsiveness results are summarized in Table 4. Analysis of
changes in DSC-R scale scores from baseline to year one revealed
the expected pattern, but changes were very small for all groups.
Patients who believed they had “much worse health” compared
to baseline had worse scores on the DSC-R scales compared to
baseline (effect sizes ranged from 0.18 to 0.51). Patients who
reported their health was “about the same” had negligible
changes in their DSC-R scores between baseline and 1-year
follow up (effect sizes ranged from -0.12 to 0.10), and there were
small or negligible improvements in DSC-R scores in patients Ta
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who believed their health was much better (effect sizes ranged
from -0.32 to -0.08). This pattern was observed across all scales,
except the “Hyperglycemic” scale.
MID were estimated to range from 0.39 to 0.60 points across
domains when estimated using distribution methods (0.5 of a
standard deviation) and from 0.00 to 0.33 points when estimated
using anchor-based methods (change for patients who reported
that they were “somewhat better” or “somewhat worse” on the
SF-36 item 2). Therefore, a conservative approach would be to
adopt the distribution-based MID for all domains.
Conclusions
The ADOPT study provided an excellent opportunity to examine
the psychometric properties of the DSC-R in a large sample of
type 2 diabetes patients. Analysis of data gathered from this
study conﬁrmed that the DSC-R has good validity and reliability.
Construct validity testing through CFA and multitrait analy-
ses conﬁrmed the validity of the DSC-R item-domain structure,
with all items loading on and correlating with the domain in
which they were included. A priori criteria for “goodness of ﬁt”
were not quite met, but in all cases the criteria were only nar-
rowly missed. Furthermore, it could be argued that different
symptom clusters should not necessarily be expected to be
(strongly) related. For example, a patient experiencing ophthal-
mologic symptoms (and associated distress) would not neces-
sarily be expected to be experiencing cardiovascular symptoms.
The Cardiovascular domain was the only domain that failed
(narrowly) to meet the criterion for internal consistency, but this
is unsurprising given that the scale includes items relating to
shortness of breath and pain/palpitations in the heart, which
would not necessarily be expected to be closely related.
Both correlations among the factors of the CFA (shown in
Fig. 2) and zero-order Pearson’s correlations between the
domains (paragraph 4 of the results) were conducted. For the
correlations between the “psychological fatigue” and “psycho-
logical cognitive” domains, there were considerable differences
between the zero-order or “raw” correlations between the
domains (0.71), and the “adjusted” interdomain correlation in
the CFA model (0.33). This difference is most likely explained
by the fact that these two factors are highly related to the Total
score (factor loading with Total score = 0.81 for “psychological
fatigue” and 0.84 for “psychological cognitive”). As the Total
score explains a large part of the variance between these two
factors, it only leaves a “residual” correlation of only 0.33
between the “psychological” domains in the model. By con-
trast, the raw correlation between the “neuropathic pain” and
“neuropathic sensoric” domains is close to the correlation
given by the model (0.62 and 0.60 respectively), and the
loading of these “neuropathic” domains on the Total score are
lower than those of the “psychological” domains (0.68 and
0.66 vs. 0.81 and 0.84). This shows that the two “neuro-
pathic” domains may have a strong “residual” correlation inde-
pendent from the Total score.
The relatively high correlation between the two “neuro-
pathic” domains could indicate the presence of a higher-order
factor. However, it was deliberately decided not to evaluate this
as part of the model, because the objective was to evaluate the ﬁt
of the original model of the DSC-R and not to try to ﬁnd the best
structure. Furthermore, it also could be argued that the two
domains should be left separate as they are distinct in terms of
the item content: one focuses on neuropathic pain while the other
asks about other neuropathic sensations. As the model ﬁt was
acceptable with this speciﬁcation and the other psychometric
results of the two separate domains were good, it was decided to
keep these two distinct (but correlated) domains separate. Future
validation of the DSC-R could further explore whether these
domains are best kept separate or if they should be combined
into a single higher-order domain.
An examination of correlations between DSC-R scores and
SF-36 scale scores suggested that the DSC-R has acceptable con-
current validity. Domains that one would expect to be related
correlated more highly than domains measuring less closely
related concepts. Correlations were generally small or moderate,
but this is unsurprising given that the DSC-R is a disease-speciﬁc
measure of symptom distress and the SF-36 is a generic measure
Table 2 Concurrent validity: Correlation coefﬁcients between DSC-R scores and SF-36 scale scores (N = 4286)
SF-36 scales
Bodily
pain
General
health
Mental
health
Physical
functioning
Role
emotional
Role
physical
Social
functioning Vitality
Mental
component
summary
Physical
component
summary
DSC-R domains
Psychological—fatigue -0.43* -0.46 -0.45 -0.41 -0.41 -0.45 -0.46 -0.69 -0.48 -0.47
n = 4256† n = 4245 n = 4249 n = 4242 n = 4232 n = 4211 n = 4256 n = 4250 n = 4177 n = 4177
Psychological—cognitive -0.37 -0.37 -0.39 -0.32 -0.38 -0.37 -0.42 -0.52 -0.42 -0.36
n = 4259 n = 4248 n = 4252 n = 4244 n = 4249 n = 4212 n = 4259 n = 4253 n = 4178 n = 4178
Neuropathic pain -0.38 -0.28 -0.25 -0.34 -0.23 -0.30 -0.32 -0.33 -0.22 -0.38
n = 4275 n = 4264 n = 4267 n = 4260 n = 4250 n = 4229 n = 4275 n = 4268 n = 4194 n = 4194
Neuropathic sensory -0.37 -0.25 -0.23 -0.28 -0.25 -0.28 -0.29 -0.30 -0.22 -0.33
n = 4270 n = 4259 n = 4262 n = 4255 n = 4244 n = 4223 n = 4270 n = 4263 n = 4188 n = 4188
Cardiovascular -0.37 -0.34 -0.30 -0.41 -0.29 -0.32 -0.35 -0.44 -0.29 -0.42
n = 4272 n = 4261 n = 4264 n = 4257 n = 4246 n = 4225 n = 4272 n = 4265 n = 4190 n = 4190
Ophthalmologic -0.27 -0.23 -0.23 -0.23 -0.25 -0.25 -0.27 -0.29 -0.24 -0.26
n = 4274 n = 4263 n = 4266 n = 4260 n = 4249 n = 4228 n = 4274 n = 4267 n = 4193 n = 4193
Hypoglycemic -0.31 -0.32 -0.45 -0.25 -0.35 -0.30 -0.42 -0.42 -0.45 -0.25
n = 4278 n = 4267 n = 4270 n = 4264 n = 4253 n = 4233 n = 4278 n = 4271 n = 4198 n = 4198
Hyperglycemic -0.29 -0.30 -0.28 -0.27 -0.26 -0.28 -0.28 -0.36 -0.28 -0.31
n = 4255 n = 4244 n = 4247 n = 4241 n = 4230 n = 4209 n = 4255 n = 4248 n = 4174 n = 4174
Total -0.47 -0.45 -0.46 -0.43 -0.41 -0.44 -0.49 -0.61 -0.47 -0.48
n = 4230 n = 4219 n = 4223 n = 4216 n = 4206 n = 4186 n = 4230 n = 4224 n = 4152 n = 4152
*Spearman’s correlation, P < 0.0001 for all correlations examined.
†Number of patients.
DSC-R, Diabetes Symptoms Checklist-Revised; SF-36, Short-Form 36.
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of health status. Indeed, the relatively small correlations provide
support for the value of a disease-speciﬁc measure such as the
DSC-R.
Analysis of DSC-R scores according to differences in clinical
variables supported the discriminative or “known groups” valid-
ity of the instrument. DSC-R scores were higher among patients
with higher BMI levels. Interestingly, a recent study in non-
diabetic obese and nonobese participants also found signiﬁcant
higher DSC-R scores in the obese subjects, further conﬁrming the
discriminative validity of the measure [23]. The ﬁnding that a
linear relationship between DSC-R scores and HbA1c levels was
not observed above HbA1c values of 7% to 8% is intriguing and
deserves further investigation.
MID was estimated using both anchor and distribution
methods, with anchor-based estimate resulting in very much
smaller MIDs than the distribution-based estimate. The applica-
bility of the anchor-based results may be limited by the appro-
priateness of the anchors used. Ideally, an anchor more closely
related to diabetes symptom-distress would have been used. In
the absence of such an anchor, the SF-36 change item was used;
however, the results should be interpreted with caution due to the
questionable appropriateness of this anchor. A conservative
approach would be to accept the MID estimated based on the
distribution approach of 0.5 of the baseline standard deviation.
This is more conservative because this distribution approach
resulted in the largest MID and would therefore require a greater
change in score in order to conclude a meaningful difference had
been achieved.
The study has a number of limitations that need to be men-
tioned. First, the study was performed in recently diagnosed
participants (less then 3 years) who had still few diabetes-related
symptoms. This was reﬂected in the high percentages of patients
who scored at ﬂoor. Despite the changes being very small, there
were still clear differences in DSC-R change scores between sub-
jects who reported changes in their health and those who reported
their health to be unchanged. Further evaluation of changes over
time in a sample of patients who have more severe diabetes
symptoms is recommended. Second, because the psychometric
validation was performed post hoc using clinical trial data, test–
retest reliability could not be assessed and should be evaluated in
future studies. Third, due to the post hoc nature of the study, we
were constrained in the other PRO and clinical measures available
for validation of the DSC-R. In particular, the criterion used to
deﬁne change groups in the responsiveness analysis was less than
optimal—further testing of responsiveness using a change crite-
rion which is focused on changes in diabetes symptoms (as
opposed to general health) is recommended as a priority.
In summary, the evidence reported here suggests that the
DSC-R has acceptable reliability, validity, and sensitivity to
changes over time, thus making it a suitable measure of diabetes
symptom burden for use in clinical research involving patients
with type 2 diabetes.
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